about
Pain in methadone patients: Time to address undertreatment and suicide risk (ANRS-Methaville trial)[Benzodiazepines and forensic aspects]Methadone induction in primary care for opioid dependence: a pragmatic randomized trial (ANRS Methaville).Factors associated with HCV risk practices in methadone-maintained patients: the importance of considering the couple in prevention interventionsInsufficient access to harm reduction measures in prisons in 5 countries (PRIDE Europe): a shared European public health concernMethadone induction in primary care (ANRS-Methaville): a phase III randomized intervention trialCorrelates of cocaine use during methadone treatment: implications for screening and clinical management (ANRS Methaville study).Determinants of improvement in quality of life of alcohol-dependent patients during an inpatient withdrawal programme.Risk Behaviors for HIV and HCV Infection Among People Who Inject Drugs in Hai Phong, Viet Nam, 2014.Decrease in self-reported offences and incarceration rates during methadone treatment: A comparison between patients switching from buprenorphine to methadone and maintenance treatment incident users (ANRS-Methaville trial).Intravenous heroin use in Haiphong, Vietnam: Need for comprehensive care including methamphetamine use-related interventions.Suicidal risk among patients enrolled in methadone maintenance treatment: HCV status and implications for suicide prevention (ANRS Methaville).Drug use in prisons: strategies for harm reduction (ANRS-PRIDE Program).Harmful alcohol consumption and patterns of substance use in HIV-infected patients receiving antiretrovirals (ANRS-EN12-VESPA Study): relevance for clinical management and intervention.[Opioid substitution therapy in France: a physician's overview].Predictors of non-adherence to methadone maintenance treatment in opioid-dependent individuals: implications for clinicians.Predictors of non-prescribed opioid use after one year of methadone treatment: an attributable-risk approach (ANRS-Methaville trial).Incidence, medical and socio-behavioural predictors of psychiatric events in an 11-year follow-up of HIV-infected patients on antiretroviral therapy.Withdrawal symptoms as a predictor of mortality in patients HIV-infected through drug use and receiving highly active antiretroviral therapy (HAART).Effect of anxiety symptoms on adherence to highly active antiretroviral therapy in HIV-infected women.Universal hepatitis B virus vaccination in French prisons: breaking down the last barriers.Self-reported injection practices among people who use drugs in French prisons: Public health implications (ANRS-Coquelicot survey 2011-2013).Determinants of benzodiazepine use in a representative population of HIV-infected individuals: the role of HIV status disclosure (ANRS-EN12-VESPA study).Variations in Cannabis Use Level and Correlates in Opiate-Users on Methadone Maintenance Treatment: A French Prospective Study.[Treatment of affective disorder in hepatitis C. A prospective study in 50 patients].Management of psychiatric disorders and addictive behaviors in patients with viral hepatitis C in France.[Management of patients with hepatitis C by French psychologists and psychiatrists: a practical investigation].[Using transient elastography as a screening tool for liver fibrosis in addiction service].Psychiatric Comorbidities among People Who Inject Drugs in Hai Phong, Vietnam: The Need for Screening and Innovative InterventionsUn observatoire français du traitement des hépatites C chez les usagers de drogue : commentaireEthyl Glucuronide for Detecting Alcohol Lapses in Patients With an Alcohol Use DisorderExposure to HIV risks among young people who use drugs (YPUD) in three cities in Vietnam: time to develop targeted interventionsIncreased Methamphetamine Use among Persons Who Inject Drugs in Hai Phong, Vietnam, and the Association with Injection and Sexual Risk Behaviors[French prisons and infectious risk: The urgent need to scale-up harm reduction interventions]HIV control programs reduce HIV incidence but not HCV incidence among people who inject drugs in HaiPhong, Vietnam
P50
Q33698816-7723FE30-B51E-4EDF-8A95-70B209580990Q34306848-BAECB3C0-964D-446D-A46A-D6B41A1FBDF7Q34506560-5FC8C8B3-F777-45A6-97AE-C56907D9D803Q34545139-AF092037-701B-4CA8-9FD8-DDB67412D988Q35823557-6FD8CF8F-384C-451B-8C48-42E5EEE82100Q36483395-225AEDF4-7939-422F-BC3C-239975C208D3Q36769571-72F4DA52-78E2-4D1A-8AE4-8205AC23A46BQ37198479-61C4AA26-CBE9-4A5D-93E4-B4C024139348Q38671256-AA78C921-66AC-4C15-A177-03880D5C20FCQ39259257-D63BFCA6-5EF5-4C32-A6B0-885E4063E35BQ40097031-638F7C56-C29B-48DA-A582-09691AD140DDQ40569274-AE80F235-D2E9-494C-BF2E-CD3E38E5B358Q40623760-B357238C-F6FC-49C9-B5E7-6900C4A23592Q42914133-A754B52C-844A-4AF0-B178-CBCB04280E43Q43288828-4BA67EE6-092E-4276-91B3-C4C8A297232CQ44341033-411017D0-77E3-4A25-BC34-466465359797Q44342159-B73780C8-6154-45AF-BB11-DE8AF10C450EQ45062702-3299539A-AE17-4A21-BB7C-5AC905A641ECQ45195642-1AAFCCC7-B2AA-4717-A3D5-69B9D1854FB4Q45211955-2227F01F-80FD-4E3A-818E-2FCE19A71156Q45374385-160D4E4A-D2B1-4EB9-AD70-DFA85D796CD8Q48362723-9C6DD4D8-2170-4D9D-B44D-7E9C4D9F9CFCQ48872951-51C44D2F-9596-48C2-A359-4E8A7B8E6CEBQ50574813-F62D7ACA-2EC1-4637-B5F7-ECED30F43C28Q50583704-77832392-3CB5-4D18-96C3-22D716518820Q51873378-23A74728-2079-4E6D-92AC-62C8278C1D88Q52295601-4612FE04-56C9-4C71-AED0-16B84D94BA15Q52303998-8CA2B503-80DD-4912-8EA1-1FD5811ABFEEQ58583260-7D3DF715-60D4-4670-AA53-023E6D300EBDQ60708032-CAF6A8FD-E7D9-4734-9CEB-52A5B2E770D3Q61639650-1B518CE2-0DCA-4530-9426-E00AEBFAC489Q89863585-B23777AD-AAB6-4A5A-9519-10BF40BD065DQ91296282-48215710-4670-474F-A803-BFE4C170097EQ91898612-040CBA37-FD2B-4B56-A91A-F1CA3EB55B2DQ93217404-0FE62D45-0A7A-4C5E-BFDC-2D91D3970AE6
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-2000-7838
@en
name
Laurent Michel
@ast
Laurent Michel
@en
Laurent Michel
@es
Laurent Michel
@nl
type
label
Laurent Michel
@ast
Laurent Michel
@en
Laurent Michel
@es
Laurent Michel
@nl
prefLabel
Laurent Michel
@ast
Laurent Michel
@en
Laurent Michel
@es
Laurent Michel
@nl
P106
P31
P496
0000-0002-2000-7838